Search results
Results from the WOW.Com Content Network
In China it has CFDA approval and over 180 treatment centres have been established in China, Hong Kong, and Korea. HIFU has been successfully used to treat cancer to destroy tumours of the bone, brain, breast, liver, pancreas, rectum, kidney, testes, and prostate. Several thousand patients have been treated with various types of tumours.
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
Compared with systemic chemotherapy, a higher proportion of the chemotherapy agents is (in theory) delivered to the lesions in the liver. [14] [15] Hepatic artery chemoembolization (HACE), sometimes called transarterial chemoembolization (TACE), combines hepatic artery embolization with hepatic artery chemo infusion. In one method, embospheres ...
Consultant interventional radiologist Dr Brian Stedman said his team had performed 300 procedures in 100 patients whose form of eye cancer known as ocular melanoma had spread to the liver, called ...
Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators in radiation oncology; however, when irradiating using external beam radiotherapy, the beam will always need to travel through healthy tissue, and the normal liver tissue is very ...
Two patients were completely cancer free and still carrying cancer-fighting cells after experimental therapy 10 years on, a new study has shown.
Percutaneous hepatic perfusion (PHP) is a regionalized, minimally-invasive approach to cancer treatment [1] currently undergoing Phase II and Phase III clinical testing.PHP treats a variety of hepatic tumors by isolating the liver and exposing the organ to high-dose chemotherapy.
Tirapazamine (SR-4233, WIN 59075) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen ().Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia.